This study is looking at a new medicine called Tigulixostat to treat gout. Gout is a type of arthritis caused by too much uric acid in the blood, called hyperuricemia. The study will last 6 months and compares Tigulixostat to a placebo (a pill with no medicine) to check safety and effectiveness. People aged 18-85 with gout can join, but they should not have had a recent gout attack or certain other health issues. Participants will be randomly assigned to one of three doses of Tigulixostat or a placebo, and they will not know which they are taking (this is called "double-blind"). Participants will have to stop any current urate-lowering therapies (ULT) and meet specific blood uric acid levels to join.

• The study lasts 6 months with multiple visits needed.
• Tigulixostat or placebo, no cost; possible risks as with any medication.
• Participants must temporarily stop current gout medications.